#Serum Institute of India (SII)

[integrimedical]

Serum Institute picks up 20% in needle-free tech company IntegriMedical

Vaccine major Serum Institute of India has acquired 20 per cent stake in medical device company IntegriMedical to advance needle-free injection technology, for an undisclosed amount.

The technology addresses needle-phobic patients, helping increase patient compliance, reduce needle-stick injuries, and enhancing the efficacy of liquid medication via needle-free dispersion, a note from the company said.

Serum Institute of India (SII) has been investing in backend companies and had in August 2021, bought out the Indian partner in SCHOTT Kaisha, securing its supplies of pharma packaging products, including vials, syringes, ampoules and cartridges used to package life-saving medication.

IntegriMedical has developed a US patented needle-free injection system (N-FIS) that utilises high-velocity jet stream using mechanical power to effectively and consistently administer biologics and drugs, the note said. N-FIS will be available in the Indian private market, offering patients and healthcare providers an alternative to traditional needle-based injections, it added, without giving timelines.

Adar Poonawalla, SII Chief Executive said, they were constantly seeking opportunities to invest in technologies that aligned with its mission. “IntegriMedical’s Needle-Free Injection Systems represent a significant advancement in drug delivery and we envision a needle-free solution to deliver vaccines,” he said, adding that it would “potentially revolutionize the way we administer vaccines”.

Read more@ https://www.thehindubusinessline.com/companies/serum-institute-picks-up-20-in-needle-free-tech-company-integrimedical/article68185400.ece

[biotichealthcare]

The report published by Kearney in collaboration with the Confederation of Indian Industry titled “Taking India’s life sciences industry to the global stage”, reported that “India’s vaccines industry can grow from $2 billion to $4 billion or even $5 billion”. This has been made possible by a number of factors prominent being the inclusion of vaccines in the product portfolios of several domestic and global pharmaceutical companies. With the pandemic kicking in 2019 end, the entire world came together to build an effective vaccine to fight against the deadly coronavirus.

This report speaks a lot about the Indian biosimilars and vaccines industries and how it is competing globally and scopes for India in the global biosimilars and vaccines industry. It lays down the challenges faced by the Indian pharmaceutical industry and how we can overcome these. It lays down abundant solutions to the challenges faced and how India can ace the Global Pharma sector and command its worthy position both in terms of volume and value.

Indian Vaccine Industry 

The global Pharmaceutical industry has made vaccines their priority. India commands a massive 40% share of the global vaccine industry by volume. India has been playing a pivotal role in combating deadly diseases for years and now the coronavirus pandemic. India is all set to grow to hold a more significant place in the global pharma industry in the coming years. With the introduction of newer and better technologies such as gene therapies, Ai-based informatics, etc has opened boundless opportunities to conduct research and experimentation and develop innovative and effective medications.

India already possesses a strong local pharma industry, fundamentally strong technical capabilities, and rich scientific acumen, that has helped us emerge as an innovational hub of the world. India is the global supplier of drugs and medicines and everybody prefers India for its low-cost manufacturing processes and affordable drugs.

However, Indian Pharmaceutical Industry still lags behind in terms of the value of our market share through being the third-largest volume producer. India faces several challenges that need to be overcome. COVID pandemic offers a great opportunity for India to take a step ahead to bag the top position both in terms of volume and value.

Massive Scope for Global Vaccine supply

There is abundant scope for the export of COVID-19 vaccines globally to countries unable to manufacture vaccines on their own. Moreover, there are several diseases globally that need vaccination, and these infectious diseases amount to more than 70% of the world population. Many countries rely on India for the supply of vaccine doses to combat various infectious diseases. Our own nation has a huge demand for vaccines owing to the huge population count and prevalence of abundant diseases such as diphtheria, tetanus, hepatitis B, measles, mumps, rubella, etc.

India has long been involved in supplying the highly required vaccines to several developing nations at the most affordable prices. So now also the world relied on India for COVID vaccine and India proved to be the biggest exporter of Covid vaccines globally. India itself faced a shortage of vaccines initially due to the heavy burden on the limited resources besides having huge commitments globally. Only two vaccine manufacturers i.e. Serum Institute of India (SII) and Bharat Biotech were operational in the beginning. With limited manufacturing resources, it became difficult to meet both domestic and global vaccine requirements.

This shows the scope for vaccine manufacturing in India provided we develop the required infrastructure and support our pharma medicine developers with the latest and advanced technologies to conduct their research. India requires a favorable statutory and political environment to lead the world with its pharmaceutical products. To be the global leader in terms of value, India needs to be more research-oriented to develop unique formulations to treat health conditions and obtaining Intellectual Property Rights. This is how India can occupy a major pharma share both in terms of volume as well as value.

[decentralvaccine]

Top Drugmaker Buys 50% Stake In Bollywood Studio

India's top vaccine maker has bought a 50% stake in a major Bollywood production company known for making popular films.

Adar Poonawalla’s Serene Production will invest 10bn rupees ($119m; £91.3m) in Karan Johar's Dharma Productions and Dharmatic Entertainment, his company said.

Poonawalla also heads the Serum Institute of India (SII), the world's largest vaccine maker by number of doses, which produced millions of Covid-19 shots for India and many other countries during the pandemic.

Poonawalla’s investment in the entertainment company is a significant move at a time when Bollywood is struggling to overcome lean times since the Covid-19 pandemic shut cinema.

[werindialive]

Why spend so much on Maldives when India has Andaman and Lakshadweep, ask Indian businessmen

The tweets from now suspended Maldives government ministers sparked a fresh controversy as the ministers criticized Indian government, Indians and PM Modi through their social media accounts. The tweets were in response to Prime Minister Modi’s endorsement of Lakshadweep as a tourist destination.

Now, the Indian business leaders have come up with their doubts for why Indian tourists pay so much to visit the island nation when India itself has such beautiful islands including Lakshadweep and Andaman.

Radhika Gupta, MD and CEO, Edelweiss Mutual Fund took to X to state her doubts. “I am obsessed with the potential of Indian tourism…the answer is (1) infrastructure and (2) marketing. The PM’s recent visit has put the spotlight on these destinations. Our hotel brands have shown us time and again that we know how to do luxury like no one else. Let’s take the best of Indian hospitality to build a world class tourism experience,” she posted.

“Our country has so many magnificent tourist destinations, with unimaginable potential; yet to be fully explored. Can any of you guess this Indian tourist haven, just from the pictures I’ve posted?” posted Adar Poonawalla, CEO, Serum Institute of India (SII).

EaseMyTrip also made an announcement stating that it is putting all the flights to Maldives on hold. “In solidarity with our nation, @EasMyTrip has suspended all Maldives flight bookings,” Co-founder and CEO Nishant Pitti posted on his social media account.

Many Indians- including sportsperson, actors and politicians- were outraged by the act of the deputy ministers. Several celebrities and people of status even cancelled their booking to Maldives to condemned the act by Maldives politicians.

For latest news India in Hindi, please subscribe to our newsletter.

[nandedlive]

Dengue vaccine | मोठी बातमी! आता डेंग्यूचा होणार अंत; वर्षभरात येणारं लस, सायरस पूनावाला यांची घोषणा

Dengue vaccine | भारतातील लस किंग सायरस पूनावाला यांनी एक मोठे विधान केले आहे ज्यात त्यांनी म्हटले आहे की ते एका वर्षात डेंग्यूवर बरा ���रणार आहेत. सिरम इन्स्टिट्यूटचे चेअरमन सायरस पूनावाला यांनी सांगितले की, वर्षभरात आम्ही डेंग्यू उपचार आणि डेंग्यूची लस (Dengue vaccine ) विकसित करू. आफ्रिकन देश आणि भारतात या नवीन लसीची खूप गरज आहे, जिथे लाखो लोकांना या आजाराची लागण होत आहे. Malaria vaccine Covishield च्या यशानंतर, SII जगात प्रथमच मलेरियाची लस लॉन्च करणार आहे. या लसीची आफ्रिकन देशांमध्ये आणि भारताच्या अंतर्गत भागातही नितांत गरज आहे, जिथे लाखो लोकांना या सामग्रीमुळे संसर्ग होत आहे. मोठ्या संख्येने स्त्रियांना संक्रमित करणाऱ्या रोगासाठी एक लस आहे, ही एक लस आहे जी गर्भाशयाला संक्रमित करते. Work started at SII Serum Institute of India एसआयआय सीरम इन्स्टिट्यूट ऑफ इंडियामध्ये काम सुरू सायरस पूनावाला यांनी पत्रकार परिषदेत डेंग्यूसंदर्भात मोठी घोषणा केली. पूनावाला यांनी डेंग्यूच्या लसीची नितांत गरज सांगितली. सिरम इन्स्टिट्यूट डेंग्यूच्या लसीवर दीर्घकाळापासून काम करत आहे. आफ्रिकन देशांव्यतिरिक्त, संपूर्ण आशिया आणि भारतात डेंग्यूमुळे बरेच लोक मरतात. अलीकडेच, सीरम इन्स्टिट्यूटच्या अहवालाने निष्कर्ष काढला की डेंग्यू लसीचा एकच डोस प्रौढांमध्ये सुरक्षित आणि चांगल्या प्रकारे सहन केला जातो. सिरम इन्स्टिट्यूटमध्ये डेंग्यूची लस तयार करण्यासाठी सतत चाचणी आणि काम केले जात आहे. There will be a vaccine for all four types या चारही प्रकारांसाठी लस असेल सिरम इन्स्टिट्यूट ऑफ इंडियाचे अध्य���्ष सायरस पूनावाला यांनी डेंग्यूची लस वर्षभरात आणण्याची घोषणा केली आहे. यामध्ये डेंग्यूच्या चारही प्रकारांवर उपचार केले जातील. सीरम इन्स्टिट्यूट लवकरच लस बाजारात आणण्याच्या प्रक्रियेकडे पावले टाकू शकते. देशात औषधाच्या प्रसारासाठी जलदगती मंजुरीसाठी विज्ञान आणि तंत्रज्ञान मंत्रालयाकडे अर्ज करण्यासारख्या गोष्टींचा यात समावेश आहे. सीरमने आपल्या तंत्रज्ञानाचा वापर करण्यासाठी यूएस स्थित बायोटेक्नॉलॉजी कंपनी (व्हिस्टेरा) सोबत सहकार्य केले आहे. जागतिक आरोग्य संघटनेच्या (WHO) आकडेवारीनुसार, दरवर्षी 10 ते 40 कोटी डेंग्यू तापाचे रुग्ण आढळतात Read the full article

[janchowk]

कोवैक्सिन टीका वाले लोगों को यात्रा मंजूरी न मिलने को सरकार ने निराधार बताया

कोवैक्सिन टीका वाले लोगों को यात्रा मंजूरी न मिलने को सरकार ने निराधार बताया

भारत सरकार ने शनिवार को उन रिपोर्टों को खारिज कर दिया, जिसमें दावा किया गया था कि जिन लोगों को कोवैक्सिन का टीका लगाया गया है, वे विदेश यात्रा के लिए योग्य नहीं हो सकते हैं क्योंकि कई देशों ने अभी तक कोवैक्सीन को मंजूरी नहीं दी है। केंद्रीय सूचना एवं प्रसारण मंत्री प्रकाश जावड़ेकर ने कल एक प्रेस वार्ता में कोवैक्सिन टीका लेने वाले लोगों के यात्रा प्रतिबंध के दावे को निराधार बताते हुये कहा कि-…

[adminnewstrust24]

America will support India amid Corona crisis, will provide raw material for Covishield

America will support India amid Corona crisis, will provide raw material for Covishield

Joe Biden /File Pic In the second wave of the Corona epidemic, the US, refusing to provide the raw materials needed for the vaccine, is finally ready. In a conversation between US National Security Advisor Jake Sullivan and Indian Security Advisor (NSA) Ajit Doval, the US has agreed to provide the raw material required for the covishield vaccine. The US had banned the export of key raw materials…

[integrimedical]

Serum Institute of India Invests in IntegriMedical

Serum Institute of India (SII) has announced a strategic investment in IntegriMedical, acquiring a 20% stake in the company, to advance Needle-Free Injection System technology.

The partnership between SII and IntegriMedical aligns with SII's vision of 'Health for All' and IntegriMedical's mission to ‘Transform Healthcare Globally’ by providing patient comfort, ensuring increased patient compliance, reducing needle-stick injuries, and enhancing the efficacy of liquid medication via needle-free dispersion.

IntegriMedical has developed a US patented Needle-Free Injection System (N-FIS) that utilises high-velocity jet stream using mechanical power to effectively and consistently administer biologics and drugs. The innovative drug delivery solution aims to alleviate pain during administration, providing needle-phobic patients with a pleasant and stress-free experience.

Read more@ https://pharmaceuticalmanufacturer.media/pharma-manufacturing-news/pharma-finance-and-investment-news/serum-institute-of-india-invests-in-integrimedical/

[unpluggedtv]

CEO Adar Poonawalla claims that due to low demand, the company stopped producing Covishield in December of last year. The largest vaccine manufacturer in the world, SII, produced the AstraZeneca Vaxzevria vaccine locally. Covishield accounts for more than 90% of all doses in India. In India, the Covid-19 vaccine has been administered in doses totaling over two billion. More than 70% of Indians, according to the federal health ministry, have received two doses or more. India began giving boosters to front-line healthcare workers, seniors, and patients with comorbid conditions in January 2022. It was later made accessible to all adults.

Read More: https://unpluggedtv.in/100-million-outdated-covid-jab-doses-are-destroyed-by-an-indian-vaccine-manufacturer/

[reportwire]

SII stopped Covishield production in Dec 2021, says CEO Adar Poonawalla

SII stopped Covishield production in Dec 2021, says CEO Adar Poonawalla

Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Thursday said the vaccine manufacturer stopped the production of Covishield vaccine starting December 2021, and of the total stock available at that time, around 100 million doses had already got expired. Speaking to reporters on the sidelines of the annual general meeting of Developing Countries Vaccine Manufacturers…

[decentralvaccine]

Children In Ivory Coast Receive New Doses Of Malaria Vaccine

—

Children in Ivory Coast received the first doses of a new, relatively cheap malaria vaccine on Monday, a step that has been hailed as a major milestone in the battle against one of the world’s most deadly diseases.

The R21 vaccine, developed by the Jenner Institute at the University of Oxford and the Serum Institute of India (SII), has been sent to several African countries and will also be administered in South Sudan Tuesday, the University of Oxford said in a statement sent to CNN.

[hummingzone]

Serum Institute of India contributes most to vaccination drive as others lag

SII has delivered more than what it had committed and helped the government keep the vaccination drive on track. (Photo source: IE) The country is all set to reach the 100-crore vaccination mark in the next couple of days. A majority of these vaccines have been supplied by Serum Institute of India (SII). As on Monday morning, the country had administered 98.55 crore doses of the Covid-19 vaccine.…

[parichaytimes]

कोरोना वैक्सीन असली या नकली?: पहचान के लिए केंद्र सरकार ने जारी की गाइडडलाइंस, राज्यों को भेजा अलर्ट

कोरोना वैक्सीन असली या नकली?: पहचान के लिए केंद्र सरकार ने जारी की गाइडडलाइंस, राज्यों को भेजा अलर्ट

न्यूज डेस्क, अमर उजाला, नई दिल्ली Published by: कीर्तिवर्धन मिश्र Updated Mon, 06 Sep 2021 12:17 AM IST सार अतिरिक्त सचिव मनोहर अगनानी ने दो सितंबर को केंद्र शासित प्रदेशों और राज्यों के सभी अतिरिक्त मुख्य सचिवों और प्रधान सचिवों (स्वास्थ्य) को लिखे पत्र में कहा, ‘‘यह अनुरोध किया जाता है कि टीकों को उपयोग से पहले सावधानीपूर्वक प्रमाणित करने की आवश्यकता है। कोविशील्ड और कोवाक्सिन वैक्सीन – फोटो…

[integrimedical]

SII invests in IntegriMedical’s Needle-Free Injection System technology

With this investment, SII will acquire a 20 per cent stake in IntegriMedical. Reportedly, the investment is expected to accelerate the development and commercialisation of the N-FIS technology

Serum Institute of India (SII), has announced an investment in IntegriMedical, acquiring a 20 per cent stake in the company, to advance Needle-Free Injection System technology.

IntegriMedical has developed a US patented Needle-Free Injection System (N-FIS) that utilises high-velocity jet stream using mechanical power to effectively and consistently administer biologics and drugs. The innovative drug delivery solution aims to alleviate pain during administration, providing needle-phobic patients with a pleasant and stress-free experience. IntegriMedical’s N-FIS has received regulatory approvals from CDSCO, CE, MDSAP and is ISO 13485 certified.

Read more@ https://www.expresspharma.in/sii-invests-in-integrimedicals-needle-free-injection-system-technology/